Saniona Logo

Saniona

Develops ion channel medicines for rare neurological diseases and epilepsy.

SANION | ST

Overview

Corporate Details

ISIN(s):
SE0005794617 (+1 more)
LEI:
549300XO4L9XNOCFCZ84
Country:
Denmark
Address:
Smedeland 26 B, 2600 GLOSTRUP
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Saniona is a clinical-stage biopharmaceutical company specializing in the discovery and development of proprietary medicines for rare diseases. A pioneer in ion channel research, the company leverages its expertise in highly specific ion channel modulation to develop treatments for neurological and psychiatric disorders, with a key focus on epilepsy. Saniona operates a robust drug discovery engine supported by a proprietary library of over 20,000 molecules, advancing a pipeline of potential new medicines through clinical trials to address high unmet medical needs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-27 08:00
Quarterly Report
Swedish 1000.5 KB
2025-11-27 08:00
Quarterly Report
English 887.7 KB
2025-09-04 08:00
Regulatory News Service
Saniona väljer SAN2668 som först-i-klassen klinisk kandidat för pediatrisk epil…
Swedish 220.1 KB
2025-09-04 08:00
Regulatory News Service
Saniona selects SAN2668 as first-in-class clinical candidate for paediatric epi…
English 218.7 KB
2025-08-28 08:00
Interim Report
Swedish 1.2 MB
2025-08-28 08:00
Interim Report
English 1.1 MB
2025-08-20 13:30
M&A Activity
Saniona ingår exklusivt licensavtal med Jazz Pharmaceuticals för att utveckla o…
Swedish 232.7 KB
2025-08-20 13:30
M&A Activity
Saniona Enters Exclusive Licensing Agreement with Jazz Pharmaceuticals to Devel…
English 233.7 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Saniona AB
Swedish 151.7 KB
2025-07-31 08:00
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in Saniona AB
English 150.7 KB
2025-06-26 17:30
Share Issue/Capital Change
Fenja Capital II A/S requests conversion of the remaining outstanding convertib…
English 146.1 KB
2025-06-26 17:30
Share Issue/Capital Change
Fenja Capital II A/S påkallar konvertering av resterande utestående konvertible…
Swedish 146.6 KB
2025-05-28 17:05
Post-Annual General Meeting Information
Kommuniké från årsstämma den 28 maj 2025 i Saniona AB
Swedish 216.1 KB
2025-05-28 17:05
Post-Annual General Meeting Information
Bulletin from the Saniona AB annual shareholders’ meeting on May 28, 2025
English 216.0 KB
2025-05-28 08:00
Earnings Release
Swedish 1.2 MB

Automate Your Workflow. Get a real-time feed of all Saniona filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Saniona

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Saniona via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-04-01 Thomas Feldthus Other Other 220,000 1,073,600.00 SEK
2025-04-01 Pierandrea Muglia Other Other 53,333 260,265.04 SEK
2025-04-01 Thomas Feldthus Other Other 30,000 146,400.00 SEK
2024-10-02 John Haurum Other Buy 67,100 60,363.16 SEK
2024-10-02 John Haurum Other Buy 12,361 51,415.58 SEK
2024-01-29 Pierandrea Muglia Other Other 53,333 219,731.96 SEK
2022-07-05 Karl Johan Bertil Sundberg Other Buy 40,000 142,128.00 SEK
2022-07-05 Thomas Feldthus Other Buy 30,000 130,590.00 SEK
2022-07-05 Thomas Feldthus Other Buy 30,000 129,600.00 SEK
2022-07-05 Thomas Feldthus Other Buy 5,221 22,685.24 SEK

Peer Companies

NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel
NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060

Talk to a Data Expert

Have a question? We'll get back to you promptly.